Intas Pharmaceuticals in collaboration with its global Accord brand subsidiaries, has acquired UDENYCA (pegfilgrastim-cbqv) ...

Minghui Pharmaceutical ( Minghui ), a late-stage clinical biopharmaceutical company, announced the closing of a $131 million ...

Emerging therapies targeting GD2, a marker highly expressed in neuroblastoma, offer tremendous promise. FDA-approved ...

Modeyso is the first and only treatment option approved by the FDA for this ultra-rare and aggressive brain tumor that affects an estimated 2,000 people in the U.S. each year, many of whom are ...